Not dead yet: The role of immunomodulators in IBD

ORLANDO — Thiopurine immunomodulators represent a potentially inexpensive and effective method for inflammatory bowel disease maintenance that can be underused as biologics became available, according to a keynote presentation from Advances in Inflammatory Bowel Disease 2019.“The challenge in our field is that all these other therapies are being marketed by drug companies and there’s no one marketing thiopurines,” Stephen B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern University Feinberg School of Medicine, told Healio GastroenterologyRead More

Share on facebook
Share on twitter
Share on linkedin